ArticleFrontiers in neurology2025
Effects of focal low energy extracorporeal shock wave treatment on reduction of sialorrhea in Parkinson's disease.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracorporeal shockwave therapy in tissue repair and regeneration.Wiener medizinische Wochenschrift (1946) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sialorrhea is a frequent and disabling non-motor symptom in Parkinson's disease (PD) and atypical parkinsonian syndromes, often exerting a serious impact on patients' health and quality of life (QoL). Botulinum toxin injections into the major salivary glands, which reduce salivary secretion, represent an established and effective therapy. However, even with adequate operator training and ultrasound guidance, transient dysphagia may occur. Low-energy extracorporeal shock wave therapy (ESWT) is a noninvasive neuromodulatory technique that has shown anticholinergic-like and antispastic effects in neurological disorders. Aims: To evaluate the effects of low-energy ESWT applied to the salivary glands as a potential treatment for sialorrhea in patients with PD or atypical parkinsonian syndromes. Methods: In this pilot observational study, 12 patients with advanced PD or atypical parkinsonism and clinically significant sialorrhea (UPDRS-II item 2 ≥ 2) underwent two weekly sessions of bilateral focal ESWT (750 impulses per gland, 0.1-0.3 mJ/mm Results: A statistically significant improvement was observed across all scales at week 4 post-treatment, with more sustained effects on DSFS and SCS-PD. Improvements were evident as early as week 1 and persisted up to week 8 for SCS-PD. DIS scores significantly decreased from baseline to week 4 ( Conclusion: Focal low-energy ESWT demonstrated efficacy in reducing sialorrhea in patients with advanced PD and atypical parkinsonism. These preliminary findings suggest a novel, well-tolerated, and noninvasive treatment approach that may improve QoL and serve as a potential alternative or adjunct to botulinum toxin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.